Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $34.50.
Several research analysts recently issued reports on the stock. Cantor Fitzgerald increased their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, March 4th.
Check Out Our Latest Analysis on Capricor Therapeutics
Institutional Trading of Capricor Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. grew its holdings in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth $68,000. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $78,000. Finally, New York State Common Retirement Fund lifted its position in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares in the last quarter. 21.68% of the stock is owned by institutional investors.
Capricor Therapeutics Price Performance
Shares of Capricor Therapeutics stock traded up $0.44 on Tuesday, hitting $13.23. 696,830 shares of the company's stock traded hands, compared to its average volume of 1,354,910. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company has a fifty day moving average of $14.23 and a two-hundred day moving average of $14.21. The company has a market capitalization of $601.57 million, a price-to-earnings ratio of -12.48 and a beta of 4.10.
About Capricor Therapeutics
(
Get Free ReportCapricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
